No Data
No Data
Chordia Therapeutics: (Correction) Partial Corrections to “Summary Financial Results for the 1st Quarter Ending August 2025 [Japanese GAAP] (Unconsolidated)”
Chordia Therapeutics --- 1Q pipeline research and development is progressing smoothly.
Chordia Therapeutics＜190A＞ announced its financial results for the first quarter of the fiscal year ending August 2025 (September-November 2024) on the 14th. The business revenue is not applicable, with an operating loss of 0.624 billion yen, an ordinary loss of 0.615 billion yen, and a quarterly net loss of 0.616 billion yen. For the first quarter of the fiscal year ending August 2024, no quarterly Financial Statements have been prepared, so the year-on-year change rate for the first quarter of the fiscal year ending August 2025 is not provided. The company is introducing a new type of antibody that has never been seen before.
The Growth 250 dropped significantly, with selling ahead due to worsening sentiment = Emerging Markets, 14th.
The Tokyo Stock Exchange Growth Market 250 Index has fallen significantly. Investor sentiment is deteriorating due to the overall decline of the Tokyo market. Ispace <9348.T>, Chordia Therapeutics <190A.T>, Cellseed <7776.T>, and others have decreased. On the other hand, N.P.C. <6255.T>, which had good earnings, reached a daily limit up. In recent IPOs, Visumo <303A.T> has fallen for four consecutive days. In the standard category, Sumishin SBI Net Bank <7163.T>.
Chordia Therapeutics---Rogosecib has been accepted for rare disease designation in the USA.
On the 10th, Chordia Therapeutics <190A> announced that its CLK inhibitor drug rogocekib has received rare disease designation as a treatment for relapsed refractory acute myeloid leukemia (AML) in the USA. This rare disease designation is a special approval system by the USA Food and Drug Administration (FDA) that supports the acceleration of the development of drugs for rare diseases. Rogosekib is for the treatment of relapsed acute myeloid leukemia.
Chordia Therapeutics: Summary of financial results for the 1st quarter of the fiscal year ending August 2025 [Japanese GAAP] (unconsolidated)
Kasumigaseki Capital, Asahi Chemicals, Toho, Bunkyo HD (14th)
※ The above Calendar is merely a schedule and may be subject to change due to corporate circumstances. --------------------------------------- January 14 (Tuesday) <135A> VRAIN <1377> Sakata Seed <138A> Hikari Food Service <1401> mbs <1407> West HD <1418> Interlife <1419> Tama Home <1430> 1st Co.